Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

رؤية الوزارة حول التحول الرقمي للقطاع الصحي


Foreword by the Minister of Health

In the following pages, we reveal a compelling vision for the future of digital health in Lebanon—an innovative blueprint developed through collaborative, forward-thinking, and inclusive efforts. With the recognition of digital technology as an integral driver of healthcare improvement, the Ministry of Public Health (MoPH) has been at the forefront, rallying essential stakeholders and orchestrating strategic discussions aimed at redefining our healthcare landscape.

This grand vision is grounded in the National Health Strategy, launched by the MoPH in January 2023. Recognizing the importance of digital health transformation, this strategy identified it as a crucial pillar. From this sturdy foundation, the Digital Health Retreat was organized on May 18, 2023. This retreat acted as a catalyst, creating an arena for stakeholders to identify the challenges and opportunities present in Lebanon's digital health ecosystem. A consensus was reached, emphasizing the pressing need for a consolidated vision that enables our healthcare system and augments health outcomes for our people.

Our healthcare sector, while resilient, faces its fair share of hurdles. With this understanding, and building upon the significant investments in digital health stipulated by the National Health Strategy, our vision aims to utilize digital solutions to overcome these barriers, thereby enriching healthcare outcomes. This is a vision of synergy, empowerment, and readiness for the evolving landscape of healthcare.

Our transformative vision transcends policy constraints. It establishes a detailed blueprint for developing a resilient digital health infrastructure. These strategies encompass a multitude of aspects—from digital platforms and mobile applications to health information exchange systems and more.
The implications of this digital health transformation are immense. From improved care coordination to enhanced population health outcomes, this vision for digital health, inherent in the National Health Strategy, is poised to serve as a guiding beacon for our future. Our journey begins here, and we invite you to join us as we map the pathway for a healthier Lebanon. Together, we can transform this vision into reality.

Vision for Digital Health Transformation
    ...
    13
    ...
ATC Name B/G Ingredients Dosage Form Price
C03BA11 ADEX G Indapamide - 1.5mg 1.5mg Tablet, prolonged release 296,989 L.L
C10AA05 ORBALIP G Atorvastatin (calcium) - 20mg 20mg Tablet 1,091,712 L.L
D07CA01 MYCICORT G Neomycin sulfate - 5mg/g, Hydrocortisone acetate - 10mg/g Ointment 485,063 L.L
G04BE03 SEGUREX G Sildenafil (citrate) - 50mg 50mg Tablet, film coated 315,803 L.L
J01CR02 BETAMOX ES G Amoxicillin - 600mg/5ml, Clavulanic Acid - 42.9mg/5ml Powder for suspension 592,635 L.L
J01FA10 AZM-500 G Azithromycin - 500mg 500mg Tablet, film coated 448,843 L.L
L02BA01 TAMOXIFENE BIOGARAN G Tamoxifen (citrate) - 10mg 10mg Tablet 415,247 L.L
M01AB05 ROFENAC D G Diclofenac free acid - 50mg 50mg Tablet, dispersible 408,528 L.L
N03AF01 NEUROTOP RETARD G Carbamazepine - 600mg 600mg Tablet, prolonged release 1,569,608 L.L
S02CA05 CETRAXAL PLUS G Ciprofloxacine HCl monohydrate - 3mg/ml, Fluocinolone acetonide - 0.25mg/ml Drops solution 795,555 L.L
A02BC01 GASTRIMUT G Omeprazole - 20mg 20mg Capsule, hard, gastro-resistant 6,720,556 L.L
A07AX03 FUROXYL G Nifuroxazide - 200mg 200mg Capsule 366,037 L.L
A10BH05 INAGLIP G Linagliptin - 5mg 5mg Tablet, film coated 1,242,606 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 179,272 L.L
C03BA11 RAWEL SR G Indapamide - 1.5mg 1.5mg Tablet, prolonged release 362,837 L.L
C10AA05 ORVASTA G Atorvastatin - 20mg 20mg Tablet, film coated 920,532 L.L
D07CB01 PANDERM G Triamcinolone acetonide - 1mg/g, Gramicidin - 0.25mg/g, Neomycin (sulfate) - 2.5mg/g, Nystatin - 100.000IU/g Cream 180,075 L.L
G04BE03 TOURNES G Sildenafil - 50mg 50mg Tablet 994,259 L.L
J01CR02 JULMENTIN ES G Amoxicillin (trihydrate) - 600mg/5ml, Clavulanic Acid (potassium) - 42.9mg/5ml 642.9mg/5ml Powder for suspension 507,972 L.L
J01FA10 ZITHROFORTE G Azithromycin (dihydrate) - 500mg 500mg Tablet, film coated 485,127 L.L
L01EA02 APO-DASATINIB G Dasatinib - 50mg 50mg Tablet 71,323,688 L.L
L02BA01 TAMOXIFEN SANDOZ G Tamoxifen (citrate) - 20mg 20mg Tablet, film coated 497,222 L.L
M01AB05 DICLO-DENK 100 RETARD G Diclofenac sodium - 100mg 100mg Tablet, sustained release 1,756,402 L.L
N03AF01 NEUROTOP RETARD G Carbamazepine - 300mg 300mg Tablet, prolonged release 931,283 L.L
P01AB01 METROLAG G Metronidazole benzoate - 125mg/5ml 125mg/5ml Syrup 391,634 L.L
R05CB06 SOLVAMUC SR G Ambroxol - 75mg 75mg Capsule 276,448 L.L
S02CA06 POLYDEXA G Dexamethasone sodium metasulfobenzoate - 1.000.000IU/100ml, Polymyxin B sulfate - 100mg/100ml, Neomycin sulfate - 650.000IU/100ml Drops solution 208,296 L.L
A02BC01 GASTRISEC G Omeprazole - 20mg 20mg Capsule 413,903 L.L
A07AX03 NIFUNAL G Nifuroxazide - 200mg 200mg Capsule, hard 217,702 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 191,913 L.L
    ...
    13
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025